Примери за използване на Perimenopausal на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Pre/perimenopausal women.
Approximately 20% of patients were pre/perimenopausal.
She was“possibly perimenopausal,” according to Dr. McArthur.
Fertility starts to decline long before the onset of any menopausal or perimenopausal symptoms.
Pre/perimenopausal women received the LHRH agonist goserelin.
I was recently diagnosed with perimenopausal low blood sugar.
During the perimenopausal stage, a woman's estrogen levels will drop significantly.
Disorders affecting the pituitary gland and hormone levels,specifically in perimenopausal or menopausal women.
Of patients were pre/perimenopausal on ovarian suppression with a GnRH agonist.
A critical metabolic enzyme called mitochondrial cytochrome oxidase was less abundant in menopausal and perimenopausal women.
Research done on eight perimenopausal women has shown that temporary restoration of ovarian activity is possible.
A key metabolic enzyme called"mitochondrial cytochrome oxidase" was found to be less abundant among menopausal and perimenopausal women.
Palbociclib in combination with fulvestrant in pre/perimenopausal women has only been studied in combination with an LHRH agonist.
In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone(LHRH) agonist.
Progesterone cream is also beneficial for younger women(perimenopausal period), because it reduces the risk of infertility, endometriosis and PMS.
In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone(LHRH) agonist.
When stress hormones go out of balance, your thyroid is often affected, too, which in turn triggers PMS,menstrual and perimenopausal symptoms and other health issues.
In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone(LHRH) agonist.
With estrogen deficiency, local estrogens are prescribed at the beginning of treatment(or systemic estrogens are prescribed if there are other symptoms of the perimenopausal period).
Treatment of pre/perimenopausal women with the combination of palbociclib plus an aromatase inhibitor should always be combined with an LHRH agonist(see section 4.4).
Study results show that after taking 100 milligrams of soy isoflavones for 12 weeks,menopausal and perimenopausal(in the early stages before menopause) helped improve the MRS(33).
Another study in 507 perimenopausal and postmenopausal women found that those who ate onions at least once a day had a 5% greater overall bone density than individuals who ate them once a month or less(27).
Prior to the start of treatment with the combination of Faslodex plus palbociclib, and throughout its duration,pre/perimenopausal women should be treated with LHRH agonists according to local clinical practice.
The CHMP introduced a warning regarding postmenopausal endocrine status, as studies have shown sub-optimal efficacy and increased frequency andseverity of adverse events in women with perimenopausal status.
Ovarian ablation orsuppression with an LHRH agonist is mandatory when pre/perimenopausal women are administered IBRANCE in combination with an aromatase inhibitor, due to the mechanism of action of aromatase inhibitors.
Vitamin D, along with adequate calcium(1200 mg of elemental calcium), has been shown in some studies to increase bone density and decrease fractures in older postmenopausal, butnot in premenopausal or perimenopausal women.
Prior to the start of treatment with the combination of palbociclib plus fulvestrant, and throughout its duration,pre/perimenopausal women should be treated with LHRH agonists according to local clinical practice.
However, women who are perimenopausal may still become pregnant until they have reached true menopause(the absence of periods for one year) and should still use contraception if they do not wish to become pregnant.
As a result, efficacy was suboptimal andhigh rates of menopausal symptoms such as hot flushes occurred, as their perimenopausal status was insufficient to suppress the feedback loop of oestrogen synthesis.
Kisqali was evaluated in a randomised, double-blind, placebo-controlled,multicentre phase III clinical study in the treatment of pre- and perimenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer in combination with a NSAI or tamoxifen plus goserelin versus placebo in combination with a NSAI or tamoxifen plus goserelin.